New drug combo aims to slow kidney failure in High-Risk patients

NCT ID NCT07624305

Not yet recruiting Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This phase 3 trial tests whether a combination of two drugs (balcinrenone and dapagliflozin) works better than dapagliflozin alone for people with advanced chronic kidney disease (stages 3b and 4). About 2,800 participants will take the combination or a placebo daily, alongside standard care. The goal is to see if the combo can delay kidney failure, reduce heart-related deaths, and prevent hospitalizations for heart failure.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

Balcinrenone and dapagliflozin combination pill

What this could lead to

If successful, this combination could offer a new treatment option to slow kidney disease progression and reduce heart complications in patients with advanced chronic kidney disease.

What could go wrong

This is a large phase 3 trial, but it hasn't started yet. The benefits over existing treatment may be modest, and there are risks like high potassium levels or side effects from the new drug combination.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

chronic kidney disease chronic renal failure syndrome

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RENAL INSUFFICIENCY, CHRONIC

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Research Site

Ciudad de Buenos Aires, C1425AGC, Argentina
Research Site

Edmonton, Alberta, T6G 2P4, Canada
Research Site

Winnipeg, Manitoba, R2V 3M3, Canada
Research Site

London, Ontario, N6A 5A5, Canada
Research Site

Toronto, Ontario, M4G 3E8, Canada
Research Site

Waterloo, Ontario, N2T 0C1, Canada
Research Site

Halifax, NS B3H 2Y9, Canada
Research Site

Magdeburg, 39120, Germany
Research Site

Kita-ku, 144-0001, Japan
Research Site

Osaka, 553-0003, Japan
Research Site

Olsztyn, 10-561, Poland
Research Site

Warsaw, 02-507, Poland
Research Site

Warsaw, 04-141, Poland
Research Site

Węgrów, 07-100, Poland
Research Site

Wroclaw, 50-981, Poland
Research Site

Żywiec, 34-300, Poland
Research Site

Anyang, 14068, South Korea
Research Site

Cheonan-si, 31151, South Korea
Research Site

Seoul, 03181, South Korea
Research Site

Seoul, 03312, South Korea
Research Site

Seoul, 04401, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Seoul, 08308, South Korea
Research Site

Changhua, 500, Taiwan
Research Site

Hualien City, 970473, Taiwan
Research Site

Kaohsiung City, 813, Taiwan
Research Site

Kaohsiung City, 833, Taiwan
Research Site

New Taipei City, 220216, Taiwan
Research Site

Taichung, 40201, Taiwan
Research Site

Taichung, 404, Taiwan
Research Site

Taichung, 40705, Taiwan
Research Site

Taichung, 433004, Taiwan
Research Site

Tainan, 70403, Taiwan
Research Site

Tainan, 710, Taiwan
Research Site

Taipei, 100, Taiwan
Research Site

Taipei, 110, Taiwan
Research Site

Taipei, 116, Taiwan
Research Site

Taoyuan, 333, Taiwan
Research Site

Zhubei, 302, Taiwan
Research Site

Da Nang, 55000, Vietnam
Research Site

Hanoi, 100000, Vietnam
Research Site

Hanoi, 10000, Vietnam
Research Site

Hà Nội, 100000, Vietnam
Research Site

Ho Chi Minh City, 700000, Vietnam
Research Site

Hochiminh City, 700000, Vietnam